An early clinical trial in individuals with the deadly brain cancer glioblastoma showed an experimental spherical nucleic acid drug developed by Northwestern University scientists was able to penetrate the blood-brain barrier and trigger the death of tumor cells. Lead investigator Priya Kumthekar, MD, explains the results of the study.